Mirum Pharmaceuticals (MIRM) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$86.01
+5.7% on the day
+16.5% over 12 months
52-week range $64.10 – $128.57
Share price and insider trades
MIRM closeInsider buyInsider sale
Bought, 12 months$9.0M
Sold, 12 months$42.2M
Insiders buying1
Insiders selling7
Mirum Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $9.0M and 7 sold $42.2M of MIRM stock on the open market.
Get emailed when insiders cluster-buy stocks like MIRM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
MIRM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $14.2M | 19 |
| Q2 2026 | — | 0 | $4.4M | 13 |
| Q1 2026 | $9.0M | 1 | $12.0M | 21 |
| Q4 2025 | — | 0 | $11.6M | 6 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.4×Last 5 sessions
Insiders' paper profit+$2.3MOn all tracked purchases +25.6%
Summary
Over the past 12 months, 1 Mirum Pharmaceuticals, Inc. insider reported open-market purchases totaling $9.0M, while 7 insiders reported sales totaling $42.2M. 39 of 59 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Eric BjerkholtCFO | Sell | 9,94344,745 held (−18%) | $98.37 | $978K | -12.6% | — |
| Sep 3SEC | Christopher PeetzCEO | Sell Plan | 21,688194,440 held (−10%) | $98.91 | $2.1M | -13.0% | — |
| Sep 3SEC | Christopher PeetzCEO | Sell Plan | 8,312216,128 held (−4%) | $98.08 | $815K | -12.3% | — |
| Sep 3SEC | Jolanda HoweSvp, Global Controller | Sell Plan | 658616 held (−52%) | $100.00 | $66K | -14.0% | — |
| Aug 19SEC | Jolanda HoweSvp, Global Controller | Sell | 40,0001,274 held (−97%) | $100.00 | $4.0M | -14.0% | — |
| Aug 12SEC | Eric BjerkholtCFO | Sell Plan | 6,00136,355 held (−14%) | $99.90 | $599K | -13.9% | — |
| Aug 11SEC | Christopher PeetzCEO | Sell Plan | 11,683202,626 held (−5%) | $98.51 | $1.2M | -12.7% | — |
| Aug 11SEC | Christopher PeetzCEO | Sell Plan | 6,017196,609 held (−3%) | $99.25 | $597K | -13.3% | — |
| Aug 11SEC | Christopher PeetzCEO | Sell Plan | 2,300194,309 held (−1%) | $100.14 | $230K | -14.1% | — |
| Aug 5SEC | Jolanda HoweSvp, Global Controller | Sell Plan | 1,8401,274 held (−59%) | $105.29 | $194K | -18.3% | — |
| Jul 8SEC | Christopher PeetzCEO | Sell Plan | 12,134202,175 held (−6%) | $121.65 | $1.5M | -29.3% | — |
| Jul 8SEC | Christopher PeetzCEO | Sell Plan | 4,181197,994 held (−2%) | $122.34 | $512K | -29.7% | — |
| Jul 8SEC | Eric BjerkholtCFO | Sell Plan | 3,12444,057 held (−7%) | $121.67 | $380K | -29.3% | — |
| Jul 8SEC | Christopher PeetzCEO | Sell Plan | 1,975196,019 held (−1%) | $123.74 | $244K | -30.5% | — |
| Jul 8SEC | Christopher PeetzCEO | Sell Plan | 1,710194,309 held (−1%) | $124.79 | $213K | -31.1% | — |
| Jul 8SEC | Eric BjerkholtCFO | Sell Plan | 1,04843,009 held (−2%) | $122.43 | $128K | -29.7% | — |
| Jul 8SEC | Eric BjerkholtCFO | Sell Plan | 52842,481 held (−1%) | $123.84 | $65K | -30.5% | — |
| Jul 8SEC | Eric BjerkholtCFO | Sell Plan | 30042,181 held (−1%) | $124.94 | $37K | -31.2% | — |
| Jul 2SEC | Jolanda HoweSvp, Global Controller | Sell Plan | 2,7213,114 held (−47%) | $120.00 | $327K | -28.3% | — |
| Jun 18SEC | Jolanda HoweSvp, Global Controller | Sell Plan | 2,5945,835 held (−31%) | $101.95 | $264K | -15.6% | — |
| Jun 9SEC | Eric BjerkholtCFO | Sell Plan | 2,25847,530 held (−5%) | $92.84 | $210K | -7.4% | — |
| Jun 9SEC | Eric BjerkholtCFO | Sell Plan | 1,56744,788 held (−3%) | $95.12 | $149K | -9.6% | — |
| Jun 9SEC | Eric BjerkholtCFO | Sell Plan | 1,17546,355 held (−2%) | $93.95 | $110K | -8.5% | — |
| Jun 2SEC | Christopher PeetzCEO | Sell Plan | 16,595205,112 held (−7%) | $95.34 | $1.6M | -9.8% | — |
| Jun 2SEC | Christopher PeetzCEO | Sell Plan | 6,926198,186 held (−3%) | $96.15 | $666K | -10.5% | — |
| Jun 2SEC | Saira RamasastryDirector | Sell Plan | 3,977 | $100.00 | $398K | -14.0% | — |
| Jun 2SEC | Christopher PeetzCEO | Sell Plan | 2,602221,707 held (−1%) | $94.64 | $246K | -9.1% | — |
| Jun 2SEC | Christopher PeetzCEO | Sell Plan | 1,973196,213 held (−1%) | $97.56 | $192K | -11.8% | — |
| Jun 2SEC | Christopher PeetzCEO | Sell Plan | 1,021195,192 held (−1%) | $98.20 | $100K | -12.4% | — |
| Jun 2SEC | Christopher PeetzCEO | Sell Plan | 883194,309 held (−0%) | $99.66 | $88K | -13.7% | — |
| May 18SEC | Saira RamasastryDirector | Sell Plan | 2,000 | $109.47 | $219K | -21.4% | — |
| Apr 16SEC | Saira RamasastryDirector | Sell Plan | 2,000 | $96.90 | $194K | -11.2% | — |
| Mar 17SEC | Christopher PeetzCEO | Sell | 40,985194,309 held (−17%) | $91.98 | $3.8M | -6.5% | — |
| Mar 17SEC | Peter RadovichCOO, President | Sell | 16,51540,272 held (−29%) | $91.98 | $1.5M | -6.5% | — |
| Mar 17SEC | Eric BjerkholtCFO | Sell | 7,28749,788 held (−13%) | $91.98 | $670K | -6.5% | — |
| Mar 17SEC | Joanne QuanChief Medical Officer | Sell | 7,28718,864 held (−28%) | $91.98 | $670K | -6.5% | — |
| Mar 17SEC | Jolanda HoweSvp, Global Controller | Sell | 4,7328,429 held (−36%) | $91.98 | $435K | -6.5% | — |
| Mar 17SEC | Saira RamasastryDirector | Sell Plan | 2,000 | $90.76 | $182K | -5.2% | — |
| Feb 17SEC | Saira RamasastryDirector | Sell Plan | 2,000 | $102.09 | $204K | -15.8% | — |
| Feb 3SEC | Christopher PeetzCEO | Sell | 9,108160,294 held (−5%) | $103.30 | $941K | -16.7% | — |
| Feb 3SEC | Peter RadovichCOO, President | Sell | 2,63120,655 held (−11%) | $103.30 | $272K | -16.7% | — |
| Feb 3SEC | Jolanda HoweSvp, Global Controller | Sell | 9684,503 held (−18%) | $103.30 | $100K | -16.7% | — |
| Jan 27SEC | Patrick J HeronDirector | Buy | 131,425459,010 held (+40%) | $68.48 | $9.0M | +25.6% | — |
| Jan 27SEC | Christopher PeetzCEO | Sell | 6,831169,402 held (−4%) | $96.19 | $657K | -10.6% | — |
| Jan 27SEC | Peter RadovichCOO, President | Sell | 3,14323,286 held (−12%) | $96.19 | $302K | -10.6% | — |
| Jan 27SEC | Eric BjerkholtCFO | Sell | 1,05343,741 held (−2%) | $96.19 | $101K | -10.6% | — |
| Jan 27SEC | Jolanda HoweSvp, Global Controller | Sell | 8423,700 held (−19%) | $96.19 | $81K | -10.6% | — |
| Jan 23SEC | Christopher PeetzCEO | Sell | 7,098163,733 held (−4%) | $93.33 | $662K | -7.8% | — |
| Jan 23SEC | Peter RadovichCOO, President | Sell | 2,38220,679 held (−10%) | $93.33 | $222K | -7.8% | — |
| Jan 23SEC | Joanne QuanChief Medical Officer | Sell | 1,82212,817 held (−12%) | $93.33 | $170K | -7.8% | — |
| Jan 23SEC | Eric BjerkholtCFO | Sell | 1,42142,127 held (−3%) | $93.33 | $133K | -7.8% | — |
| Jan 23SEC | Jolanda HoweSvp, Global Controller | Sell | 9263,042 held (−23%) | $93.33 | $86K | -7.8% | — |
| Jan 21SEC | Joanne QuanChief Medical Officer | Sell | 6,91111,305 held (−38%) | $90.27 | $624K | -4.7% | — |
| Jan 16SEC | Saira RamasastryDirector | Sell Plan | 2,000 | $90.99 | $182K | -5.5% | — |
| Dec 23SEC | Michael G GreyDirector | Sell Plan | 50,000 | $78.00 | $3.9M | +10.3% | — |
| Dec 23SEC | Saira RamasastryDirector | Sell Plan | 5,000 | $80.00 | $400K | +7.5% | — |
| Dec 19SEC | Saira RamasastryDirector | Sell Plan | 1,000 | $70.00 | $70K | +22.9% | — |
| Dec 19SEC | Saira RamasastryDirector | Sell Plan | 1,0001,000 held (−50%) | $69.46 | $69K | +23.8% | — |
| Dec 2SEC | Michael G GreyDirector | Sell Plan | 50,000 | $74.00 | $3.7M | +16.2% | — |
| Nov 25SEC | Michael G GreyDirector | Sell Plan | 50,000 | $70.00 | $3.5M | +22.9% | — |
Insiders at Mirum Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Patrick J HeronDirector | $9.0M | — | Jan 27, 2026 | — |
| Christopher PeetzCEO | — | $16.3M | Sep 3, 2026 | — |
| Michael G GreyDirector | — | $11.1M | Dec 23, 2025 | — |
| Jolanda HoweSvp, Global Controller | — | $5.6M | Sep 3, 2026 | — |
| Eric BjerkholtCFO | — | $3.6M | Sep 15, 2026 | — |
| Peter RadovichCOO, President | — | $2.3M | Mar 17, 2026 | — |
| Saira RamasastryDirector | — | $1.9M | Jun 2, 2026 | — |
| Joanne QuanChief Medical Officer | — | $1.5M | Mar 17, 2026 | — |
MIRM stock: common questions
Are Mirum Pharmaceuticals, Inc. insiders buying MIRM stock?
In the past 12 months, 1 insiders reported open-market purchases of MIRM worth $9.0M. The latest was Director Patrick J Heron bought $9.0M of MIRM at $68.48 — first open-market purchase in our records; raises the stake by 40%.
Are Mirum Pharmaceuticals, Inc. insiders selling MIRM stock?
7 insiders reported sales worth $42.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MIRM's 52-week range?
Over the past year MIRM has traded between $64.10 and $128.57. It last closed at $86.01 on Oct 9, 2026.